Results 111 to 120 of about 1,890 (188)

Ticagrelor removal by CytoSorb® in patients requiring emergent or urgent cardiac surgery: a UK-based cost-utility analysis [PDF]

, 2019
Background: Acute coronary syndrome patients receiving dual antiplatelet therapy who need emergent or urgent cardiac surgery are at high risk of major bleeding, which can impair postoperative outcomes.

core   +1 more source

The use of CytoSorb therapy in COVID-19 cytokine storm

, 2021
The CytoSorb whole blood adsorber is a CE approved medical device for the extracorporeal removal of cytokines. The aim is to reduce excessive cytokine levels and other inflammatory mediators, while maintaining the physiological immune response. It is documented in the literature that critically ill patients with COVID-19 had the increased levels of ...
openaire   +1 more source

2025 ACVIM Forum Research Abstract Program

Journal of Veterinary Internal Medicine, Volume 39, Issue 6, November/December 2025.
wiley   +1 more source

Clindamycin clearance during Cytosorb hemoadsorption: A case report and pharmacokinetic study.

, 2019
Panton-Valentine leucocidin producing methicillin-resistant Staphylococcus aureus infections are rare but associated with very high mortality rates.
Poli, E.C., André, P., Ferry, T., Simoni, C., Buclin, T., Perez, M.H., Longchamp, D., Schneider, A.G., Ferry T, Simoni C, Perez MH, Buclin T, Longchamp D, Schneider AG, Poli EC, André P   +15 more
core   +1 more source

Cytosorb treatment in severe COVID-19 cardiac and pulmonary disease [PDF]

European Heart Journal - Case Reports, 2021
Michele Ciabatti, Lucia Martinese, Antonio Quacquarelli, Maurizio Pieroni, Marco Feri, Leonardo Bolognese   +5 more
openaire   +2 more sources

Ticagrelor Removal by CytoSorb\uae in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis

, 2020
\ua9 2019, The Author(s).Background: Acute coronary syndrome patients receiving dual antiplatelet therapy who need emergent or urgent cardiac surgery are at high risk of major bleeding, which can impair postoperative outcomes.
Javanbakht M, Branagan-Harris M, Cook SF, Mortensen E, Rahimi K, Rezaei Hemami M, Trevor M, Adam D, Preissing F, Scheier J, Degener F   +10 more
core   +1 more source

Fulminant Red Yeast Rice-Associated Rhabdomyolysis with Acute Liver Injury and Hyperkalemia Treated with Extracorporeal Blood Purification Using CytoSorb

Drug, Healthcare and Patient Safety
Marko Kurnik,1 Tilen Markelj,1 Borut Žgavc,1 Barbara Hudournik,1 Marija Meznarič,2 Matej Podbregar1,2 1Department of Internal Intensive Medicine, General Hospital Celje, Celje, Slovenia; 2Faculty of Medicine, University of Ljubljana ...
Kurnik M, Markelj T, Žgavc B, Hudournik B, Meznarič M, Podbregar M   +5 more
doaj  

Population Pharmacokinetics of Amikacin and Monte Carlo Simulation Study in Critically Ill Septic Patients Undergoing Continuous Renal Replacement Therapy with CytoSorb^® or oXiris^®. [PDF]

Pharmaceutics
Špirić N, Kovačević P, Kovačević T, Momčićević D, Dragić S, Zlojutro B, Jandrić M, Barić G, Miljković B, Ostermann M, Vučićević K.   +10 more
europepmc   +1 more source

Effects of CytoSorb^® hemoadsorption therapy on serum myoglobin and creatine kinase levels in severe rhabdomyolysis: a systematic review and meta-analysis. [PDF]

BMC Nephrol
Reynolds A, Scharf C, Forni LG, Koo TY, Büttner S, Humbert V, Kielstein J, Kindgen-Milles D, Meiser A, Mitzner S, Molnar Z, Premuzic V, Taborda-Küpper MS, Weidhase L, Kribben A.   +14 more
europepmc   +1 more source

Cytokine and Vasopressor Trajectories During Continuous Renal Replacement Therapy with oXiris, CytoSorb, or Standard Haemofilters in Sepsis-Associated Acute Kidney Injury: An Exploratory Retrospective Cohort Study. [PDF]

Biomedicines
Porosnicu TM, Gindac C, Elagez A, Papurica M, Pescariu AS, Bratosin F, Hogea E, Sandesc D, Bedreag O.   +8 more
europepmc   +1 more source